Compare Nu Holdings Ltd (NU) vs TG Therapeutics Inc (TGTX) Price & Performance

NU Holdings stock trades at $15.33, down 0.26% today, with a bullish technical outlook and strong fundamental growth. The company reported record Q2 2026 results with $1 billion net income and 39% revenue growth year-over-year, driven by expanding customer base and AI integration. Analyst consensus is a Buy with a $17.20 price target, reflecting confidence in sustained profitability and market expansion in Brazil and Mexico.

The stock presents a compelling growth opportunity with robust earnings momentum and positive sentiment, though risks include credit quality concerns and competitive pressures. Upside potential exists if execution continues, but investors should monitor loan performance and macroeconomic factors in key markets.

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.